A pleasure having Dr. Julien Kirchgesner, Associate Professor, Department of Gastroenterology at Saint-Antoine Hospital, AP-HP, and Head of FORECAST, Pierre Louis Institute of Epidemiology and Public Health, INSERM at Sorbonne University in Paris visiting PREDICT.

Exciting to hear about the ambitious development and validation of a new framework using multiple sources of real-world data to assess the benefit-risk balance of advanced therapies in inflammatory bowel disease.